Change of EU home Member State
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION Acacia Pharma Group plc  Change of EU home Member State…
Month: February 2021
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA)…
Immunicum AB (publ) Announces Year-End Results 2020
Press Release 18 February 2021 Immunicum AB (publ) Announces Year-End Results 2020 OCTOBER-DECEMBER IN SUMMARY…
Y-mAbs Announces Pricing of Public Offering of Common Stock
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology…
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time…
In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations
New York, NY and Mainz, Germany, February 17, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE:…
Golden Leaf Announces Non-Brokered Private Placement of up to C$11,000,000
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTIONÂ OR DISSEMINATION DIRECTLY OR…
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss,…
Better Choice Company Retains Emerging Markets Consulting, LLC (EMC) and Winning Media to Provide Investor/Public Relations Services
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQB: BTTR) (“Better Choice”),…
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare…
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a…
Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
VANCOUVER, British Columbia and SEATTLE, Feb. 17, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ:…
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the…
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical…
Shockwave Medical Reports Fourth Quarter and Full Year 2020 Financial Results
SANTA CLARA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or…
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced…
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and…